Needham & Company LLC reaffirmed their hold rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a report released on Tuesday.

“Regulus announced this morning another revision to the Sanofi collaboration agreement, in which Sanofi has been granted a WW exclusive license to RG-012. Sanofi will now assume control of the development program, including all costs going forward. Regulus will receive $7M upfront and is entitled to $40M in development milestone payments. Regulus had suspended enrollment in the Phase 2 RG-012 program in Alport Syndrome earlier this year in order to conserve cash while renegotiating terms with Sanofi. The transaction extends cash to 2Q19, but under new terms, Regulus will not be receiving any revenue from the program after Phase 2 is completed by Sanofi.”,” the firm’s analyst commented.

Several other research firms also recently commented on RGLS. Leerink Swann downgraded Regulus Therapeutics from an outperform rating to a market perform rating in a research report on Tuesday, July 10th. Wedbush restated a hold rating and set a $1.00 target price on shares of Regulus Therapeutics in a research report on Friday, August 10th. Zacks Investment Research upgraded Regulus Therapeutics from a hold rating to a buy rating and set a $2.00 target price for the company in a research report on Saturday, October 13th. Finally, ValuEngine upgraded Regulus Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 2nd. Nine investment analysts have rated the stock with a hold rating, The stock presently has an average rating of Hold and a consensus price target of $1.42.

Shares of NASDAQ:RGLS traded down $0.12 during trading on Tuesday, hitting $1.65. 153,595 shares of the stock were exchanged, compared to its average volume of 1,211,956. Regulus Therapeutics has a 1-year low of $1.57 and a 1-year high of $17.28. The firm has a market capitalization of $15.54 million, a PE ratio of -0.14 and a beta of 1.78.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($1.18) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.25) by $0.07. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative return on equity of 205.48% and a negative net margin of 83,538.89%. As a group, equities research analysts anticipate that Regulus Therapeutics will post -5.02 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Regulus Therapeutics stock. A.R.T. Advisors LLC acquired a new stake in Regulus Therapeutics Inc (NASDAQ:RGLS) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 169,416 shares of the biopharmaceutical company’s stock, valued at approximately $121,000. A.R.T. Advisors LLC owned about 0.16% of Regulus Therapeutics as of its most recent filing with the SEC.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Read More: Dividend Aristocrat Index

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with's FREE daily email newsletter.